[
  {
    "ts": "2026-02-04T14:15:00+00:00",
    "headline": "Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.",
    "summary": "Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc. Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for active traders seeking amplified exposure to innovative companies at the forefront of biotechnology and life sciences. MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its l",
    "url": "https://finance.yahoo.com/news/defiance-launches-mrnx-first-daily-141500000.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "f9af5708-5f94-33e2-9547-728457edeb4d",
      "content": {
        "id": "f9af5708-5f94-33e2-9547-728457edeb4d",
        "contentType": "STORY",
        "title": "Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.",
        "description": "",
        "summary": "Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc. Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for active traders seeking amplified exposure to innovative companies at the forefront of biotechnology and life sciences. MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its l",
        "pubDate": "2026-02-04T14:15:00Z",
        "displayTime": "2026-02-04T14:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/dc74227d86810998402b72d2c80b0dfc",
          "originalWidth": 1000,
          "originalHeight": 1000,
          "caption": "Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for active traders seeking amplified exposure to innovative companies at the forefront of biotechnology and life sciences.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o0GZDlO2sFnQeZ5SZyWxvw--~B/aD0xMDAwO3c9MTAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dc74227d86810998402b72d2c80b0dfc.cf.webp",
              "width": 1000,
              "height": 1000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jhvSMMB8vdNbobbD2oz_DA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/dc74227d86810998402b72d2c80b0dfc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/defiance-launches-mrnx-first-daily-141500000.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/defiance-launches-mrnx-first-daily-141500000.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T18:40:18+00:00",
    "headline": "Jim Cramer on Moderna: “Even Though the Stock’s on the Mend, There Are Many Pharma and Biotech Names That I Like Better”",
    "summary": "Moderna, Inc. (NASDAQ:MRNA) is one of the noteworthy S&P 500 stocks Jim Cramer highlighted. Cramer highlighted that the company is likely to remain unprofitable for “years to come,” as he stated: Next, let’s go back to the second-best performer in the S&P for January, and that’s Moderna. That was up nearly 50%, and this was… […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-moderna-even-though-184018949.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "b3372566-732d-33c3-a6fe-90d07c615ee1",
      "content": {
        "id": "b3372566-732d-33c3-a6fe-90d07c615ee1",
        "contentType": "STORY",
        "title": "Jim Cramer on Moderna: “Even Though the Stock’s on the Mend, There Are Many Pharma and Biotech Names That I Like Better”",
        "description": "",
        "summary": "Moderna, Inc. (NASDAQ:MRNA) is one of the noteworthy S&P 500 stocks Jim Cramer highlighted. Cramer highlighted that the company is likely to remain unprofitable for “years to come,” as he stated: Next, let’s go back to the second-best performer in the S&P for January, and that’s Moderna. That was up nearly 50%, and this was… […]",
        "pubDate": "2026-02-04T18:40:18Z",
        "displayTime": "2026-02-04T18:40:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8249220b1710e407dbf8958264db8280",
          "originalWidth": 1920,
          "originalHeight": 1280,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lxe2r2n2Nijz2mfCCmT.Ww--~B/aD0xMjgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/8249220b1710e407dbf8958264db8280.cf.webp",
              "width": 1920,
              "height": 1280,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0gBapk1Nw.YlUdmA3ihFIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8249220b1710e407dbf8958264db8280.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-moderna-even-though-184018949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-moderna-even-though-184018949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]